目的了解和分析去氨加压素在临床应用中不良反应，促进临床合理用药。
Objective To study the adverse drug reaction (ADR) of desmopressin (DDAVP) in clinical application, improving clinical medication.
在经皮肾穿刺患者中，穿刺前给予去氨加压素减少出血风险、减少血肿大小，而不增加住院费用。
Prebiopsy desmopressin administration decreases the risk of bleeding and hematoma size in patients undergoing percutaneous kidney biopsy without a cost increase.
如果患者需要要继续用药，应选择口服去氨加压素，并且从最低剂量开始增量，直到控制住症状。
If ongoing treatment is considered necessary, patients should be switched to the lowest starting dose of an oral formulation, with the dose increased only if necessary to control symptoms.
尽管这不是一个设有对照的试验，但研究者断定去氨加压素能安全有效地治疗65岁及65岁以上患者的重度夜尿症。
Although this was not a controlled trial, they concluded that desmopressin is "safe and effective in the treatment of severe nocturia in patients 65 years old and older."
上述结果帮助了生理学家理解了为什么去氨加压素对约30%的尿床儿童(又称夜间遗尿症)不起作用，而这个药物对其他70%的尿床儿童却成功治疗。
The finding helps physiologists understand why about 30% of children who suffer from bedwetting (nocturnal enuresis) do not respond to desmopressin, a drug that successfully treats the other 70%.
上述结果帮助了生理学家理解了为什么去氨加压素对约30%的尿床儿童(又称夜间遗尿症)不起作用，而这个药物对其他70%的尿床儿童却成功治疗。
The finding helps physiologists understand why about 30% of children who suffer from bedwetting (nocturnal enuresis) do not respond to desmopressin, a drug that successfully treats the other 70%.
应用推荐